ABSTRACT
T he proof of the principle, that many tumors are characterized by a high expression of somatostatin receptors, has provided the background for the use of somatostatin analogs in the diagnostic process and in the therapy of these tumors. At present, somatostatin receptor scintigraphy can be adequately used particularly in neuroendocrine tumors. When compared with other techniques, the sensitivity of radionuclide examination is much greater in the visualization of primary tumors and its metastases. This technique is also used for preliminary assessment of the degree of malignancy, therefore it could serve as a background for the treatment strategy and can help to evaluate progress of the disease.
